Activity of novel ceftibuten-avibactam, ceftazidime-avibactam, and comparators against a challenge set of Enterobacterales from outpatient centers and nursing homes across the United States (2022–2024)

Aliaa Fouad; April M. Bobenchik; Robin Chamberland; Andrew E. Clark; Holly K. Huse; Isabella W. Martin; A. Brian Mochon; Erik Munson; Maroun M. Sfeir; Monica Srodon; Kimberly Taylor; Yungchou Wang; Lars F. Westblade; David P. Nicolau; Tomefa E. Asempa

doi:10.1128/aac.01867-24

Activity of novel ceftibuten-avibactam, ceftazidime-avibactam, and comparators against a challenge set of Enterobacterales from outpatient centers and nursing homes across the United States (2022–2024)

Aliaa Fouad, April M. Bobenchik, Robin Chamberland, Andrew E. Clark, Holly K. Huse, Isabella W. Martin, A. Brian Mochon, Erik Munson, Maroun M. Sfeir, Monica Srodon, Kimberly Taylor, Yungchou Wang, Lars F. Westblade, David P. Nicolau, Tomefa E. Asempa

Department of Pathology and Laboratory Medicine

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Ceftibuten is being developed in combination with the oral prodrug of avibactam. Outpatient isolates (n = 500) from 11 US states underwent susceptibility testing with manual broth microdilution. Ceftibuten had susceptibility rates of 64% (CLSI) and 23% (EUCAST). Ceftibuten-avibactam achieved 96.4% inhibition at MIC ≤ 1 µg/mL. Susceptibility rates were as follows: cefpodoxime (2.6%), ceftriaxone (1%), ceftazidime-avibactam (99.6%), tebipenem (89%), ertapenem (94.4%), levofloxacin (26.6%), trimethoprim-sulfamethoxazole (40.2%), and fosfomycin (96.8%). Ceftibuten-avibactam demonstrates potent in vitro activity against cephalosporin non-susceptible isolates.

Original language	English (US)
Journal	Antimicrobial agents and chemotherapy
Volume	69
Issue number	5
DOIs	https://doi.org/10.1128/aac.01867-24
State	Published - May 2025

All Science Journal Classification (ASJC) codes

Pharmacology
Pharmacology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1128/aac.01867-24

Cite this

Fouad, A., Bobenchik, A. M., Chamberland, R., Clark, A. E., Huse, H. K., Martin, I. W., Mochon, A. B., Munson, E., Sfeir, M. M., Srodon, M., Taylor, K., Wang, Y., Westblade, L. F., Nicolau, D. P., & Asempa, T. E. (2025). Activity of novel ceftibuten-avibactam, ceftazidime-avibactam, and comparators against a challenge set of Enterobacterales from outpatient centers and nursing homes across the United States (2022–2024). Antimicrobial agents and chemotherapy, 69(5). https://doi.org/10.1128/aac.01867-24

@article{8cc4b55fb594454180eb256d67c58816,

title = "Activity of novel ceftibuten-avibactam, ceftazidime-avibactam, and comparators against a challenge set of Enterobacterales from outpatient centers and nursing homes across the United States (2022–2024)",

abstract = "Ceftibuten is being developed in combination with the oral prodrug of avibactam. Outpatient isolates (n = 500) from 11 US states underwent susceptibility testing with manual broth microdilution. Ceftibuten had susceptibility rates of 64\% (CLSI) and 23\% (EUCAST). Ceftibuten-avibactam achieved 96.4\% inhibition at MIC ≤ 1 µg/mL. Susceptibility rates were as follows: cefpodoxime (2.6\%), ceftriaxone (1\%), ceftazidime-avibactam (99.6\%), tebipenem (89\%), ertapenem (94.4\%), levofloxacin (26.6\%), trimethoprim-sulfamethoxazole (40.2\%), and fosfomycin (96.8\%). Ceftibuten-avibactam demonstrates potent in vitro activity against cephalosporin non-susceptible isolates.",

author = "Aliaa Fouad and Bobenchik, \{April M.\} and Robin Chamberland and Clark, \{Andrew E.\} and Huse, \{Holly K.\} and Martin, \{Isabella W.\} and Mochon, \{A. Brian\} and Erik Munson and Sfeir, \{Maroun M.\} and Monica Srodon and Kimberly Taylor and Yungchou Wang and Westblade, \{Lars F.\} and Nicolau, \{David P.\} and Asempa, \{Tomefa E.\}",

note = "Publisher Copyright: Copyright {\textcopyright} 2025 Fouad et al.",

year = "2025",

month = may,

doi = "10.1128/aac.01867-24",

language = "English (US)",

volume = "69",

journal = "Antimicrobial agents and chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "5",

}

Fouad, A, Bobenchik, AM, Chamberland, R, Clark, AE, Huse, HK, Martin, IW, Mochon, AB, Munson, E, Sfeir, MM, Srodon, M, Taylor, K, Wang, Y, Westblade, LF, Nicolau, DP & Asempa, TE 2025, 'Activity of novel ceftibuten-avibactam, ceftazidime-avibactam, and comparators against a challenge set of Enterobacterales from outpatient centers and nursing homes across the United States (2022–2024)', Antimicrobial agents and chemotherapy, vol. 69, no. 5. https://doi.org/10.1128/aac.01867-24

Activity of novel ceftibuten-avibactam, ceftazidime-avibactam, and comparators against a challenge set of Enterobacterales from outpatient centers and nursing homes across the United States (2022–2024). / Fouad, Aliaa; Bobenchik, April M.; Chamberland, Robin et al.
In: Antimicrobial agents and chemotherapy, Vol. 69, No. 5, 05.2025.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Activity of novel ceftibuten-avibactam, ceftazidime-avibactam, and comparators against a challenge set of Enterobacterales from outpatient centers and nursing homes across the United States (2022–2024)

AU - Fouad, Aliaa

AU - Bobenchik, April M.

AU - Chamberland, Robin

AU - Clark, Andrew E.

AU - Huse, Holly K.

AU - Martin, Isabella W.

AU - Mochon, A. Brian

AU - Munson, Erik

AU - Sfeir, Maroun M.

AU - Srodon, Monica

AU - Taylor, Kimberly

AU - Wang, Yungchou

AU - Westblade, Lars F.

AU - Nicolau, David P.

AU - Asempa, Tomefa E.

PY - 2025/5

Y1 - 2025/5

N2 - Ceftibuten is being developed in combination with the oral prodrug of avibactam. Outpatient isolates (n = 500) from 11 US states underwent susceptibility testing with manual broth microdilution. Ceftibuten had susceptibility rates of 64% (CLSI) and 23% (EUCAST). Ceftibuten-avibactam achieved 96.4% inhibition at MIC ≤ 1 µg/mL. Susceptibility rates were as follows: cefpodoxime (2.6%), ceftriaxone (1%), ceftazidime-avibactam (99.6%), tebipenem (89%), ertapenem (94.4%), levofloxacin (26.6%), trimethoprim-sulfamethoxazole (40.2%), and fosfomycin (96.8%). Ceftibuten-avibactam demonstrates potent in vitro activity against cephalosporin non-susceptible isolates.

AB - Ceftibuten is being developed in combination with the oral prodrug of avibactam. Outpatient isolates (n = 500) from 11 US states underwent susceptibility testing with manual broth microdilution. Ceftibuten had susceptibility rates of 64% (CLSI) and 23% (EUCAST). Ceftibuten-avibactam achieved 96.4% inhibition at MIC ≤ 1 µg/mL. Susceptibility rates were as follows: cefpodoxime (2.6%), ceftriaxone (1%), ceftazidime-avibactam (99.6%), tebipenem (89%), ertapenem (94.4%), levofloxacin (26.6%), trimethoprim-sulfamethoxazole (40.2%), and fosfomycin (96.8%). Ceftibuten-avibactam demonstrates potent in vitro activity against cephalosporin non-susceptible isolates.

UR - https://www.scopus.com/pages/publications/105004745721

UR - https://www.scopus.com/inward/citedby.url?scp=105004745721&partnerID=8YFLogxK

U2 - 10.1128/aac.01867-24

DO - 10.1128/aac.01867-24

M3 - Article

C2 - 40178307

AN - SCOPUS:105004745721

SN - 0066-4804

VL - 69

JO - Antimicrobial agents and chemotherapy

JF - Antimicrobial agents and chemotherapy

IS - 5

ER -

Activity of novel ceftibuten-avibactam, ceftazidime-avibactam, and comparators against a challenge set of Enterobacterales from outpatient centers and nursing homes across the United States (2022–2024)

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this